Benzo[c][2,6]naphthyridine CK2α Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CK2α inhibitors face challenges in selectivity, often targeting the conserved ATP binding site, leading to poor specificity for CK2α over other kinases, necessitating the development of potent and selective inhibitors that bind to the catalytic ATP site and interact with other areas of CK2α to effectively inhibit CK2α activity in proliferative disorders and other conditions.
Innovation Solution
Development of novel therapeutic compounds, specifically designed to inhibit Casein Kinase 2 alpha (CK2α) by binding to the catalytic ATP site and interacting with the αD site, enhancing selectivity and potency in targeting CK2α for the treatment of cancers, viral infections, inflammation, diabetes, vascular disorders, and neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CK2α inhibitors target the highly conserved ATP binding site, then potent enzyme inhibition is achieved, but selectivity over other kinases deteriorates
Solution Approach 1:
The inhibitor is divided into distinct functional segments: an ATP-binding moiety (for potent enzyme inhibition) and an αD-site interacting moiety (for selectivity). This segmentation allows each part to fulfill its specific role independently, resolving the contradiction between potency and selectivity.
Solution Approach 2:
Different regions of the inhibitor molecule are designed with specific properties: one region is optimized for ATP-site binding (potency) while another region is optimized for αD-site interaction (selectivity). This local differentiation enables the molecule to simultaneously achieve both potent inhibition and high selectivity.
2Reliability
If existing CK2α inhibitors are used, then CK2α activity is inhibited, but poor selectivity leads to off-target effects on other kinases
Solution Approach 1:
The αD-site interaction moiety acts as an intermediary that provides steric and electrostatic discrimination between CK2α and other kinases. This intermediary element mediates the selectivity by forming specific interactions unique to CK2α's αD-site architecture, preventing off-target effects while maintaining CK2α inhibition.
3Object-affected harmful factors
If dual-site binding inhibitors are designed, then selectivity is enhanced, but molecular complexity increases
Solution Approach 1:
Two separate functional elements (ATP-binding moiety and αD-site interacting moiety) are merged into a single inhibitor molecule. This merging achieves dual-site binding capability while maintaining a manageable molecular structure through strategic linkage of the two moieties.
Solution Approach 2:
The inhibitor molecule is designed with multi-functionality, where a single compound performs both ATP-site binding and αD-site interaction. This universal design allows one molecule to achieve multiple objectives (potency and selectivity) without requiring separate compounds for each function.
Data Source
AI summary
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof:wherein R1, Q, Ra, Rb, Rc, Rd and Re are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.